Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Join Us
    • Values & Culture
    • Perks & Benefits
    • Explore Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Cash Flow
  • Stock Data
    • TSX: APS
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Aptose Biosciences Provides Update on Reverse Stock Split

Jun 05, 2023 7:30am EDT

Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023

May 31, 2023 7:30am EDT

Aptose Enters into $25 Million Committed Equity Facility

May 25, 2023 4:14pm EDT

Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders

May 23, 2023 5:30pm EDT

Aptose Reports Results for the First Quarter 2023

May 08, 2023 4:01pm EDT

Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference

May 04, 2023 7:01am EDT

Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023

Apr 24, 2023 7:01am EDT

Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference

Apr 10, 2023 4:01pm EDT

Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium

Mar 28, 2023 4:01pm EDT

Aptose Reports Results for the Fourth Quarter and Full Year 2022

Mar 23, 2023 4:44pm EDT
RSS
  • Prev
    • 1...
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • ...33
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed
    © 2025 Aptose Biosciences Inc. All Rights Reserved.
    Privacy Policy Clinical Trials Policy Disclaimer Sitemap Manage Cookie Preferences